Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

6533b7ddfe1ef96bd1275588

RESEARCH PRODUCT

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

Melchiorre Cervello Erika Amore Angela Scala Daniele Balasus Chiara Botto Antonino Mazzaglia Giuseppe Sortino Antonina Azzolina Maria Luisa Bondì

subject

Niacinamide Erythrocytes Polymers and Plastics Cell Survival Adamantane Drug Compounding Supramolecular chemistry Bioengineering Nanotechnology Adamantane Antineoplastic Agents Binding Competitive Hemolysis Amphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cells HCC cells Biomaterials chemistry.chemical_compound Surface-Active Agents In vivo Cell Line Tumor Amphiphile Materials Chemistry Humans chemistry.chemical_classification Cyclodextrins Aqueous solution Cyclodextrin Phenylurea Compounds Sorafenib Fluorescence Combinatorial chemistry digestive system diseases Nanostructures BINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLES Drug Liberation Kinetics nanoassemblie cyclodextrin chemistry Delayed-Action Preparations Proton NMR Hepatocytes

description

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role of the aCD cavity in the interaction between drug and amphiphile. Nanoassemblies based on SC6OH/Sor display size of similar to 200 nm, negative zeta-potential (zeta = -11 mV), and both maximum loading capacity (LC similar to 17%) and entrapment efficiency (EE similar to 100%). Kinetic release profiles show a slower release of Sor from nanoassemblies with respect to the free drug. SC6OH/Sor nanoassemblies have very low hemolytic activity and high efficiency in vitro in decreasing cell growth and viability of HOC cell lines, such as HepG2, Hep3B, and PLC/PRF/5, opening promising chances to their in vivo applications.

year	journal	country	edition	language
2015-01-01

10.1021/acs.biomac.5b01082 https://publications.cnr.it/doc/336347